Companies › TScan Therapeutics
5 active drug programs in 7 registered trials: 6 Phase 1, 1 Phase 3; Oncology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| TSC-101 T-cell receptor engineered donor T cells targeting HA-2 | HA2 | Phase 3 | AML | Jun 2028 |
| TSC-200-A0201 Autologous TCR-T cell therapy targeting cancer-associated antigens presented on HLA molecu | – | Phase 1 | Head and Neck Cancer | Dec 2026 |
| TSC-204-A0201 Autologous TCR-T cell therapy targeting cancer-associated antigens presented on HLA molecu | – | Phase 1 | Head and Neck Cancer | Dec 2026 |
| TSC-204-C0702 Autologous TCR-T cell therapy targeting cancer-associated antigens presented on HLA molecu | – | Phase 1 | Head and Neck Cancer | Dec 2026 |
| TSC-100 T-cell receptor engineered donor T cells targeting HA-1 antigen | – | Phase 1 | AML | Jun 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05973487 | TSC-204-A0201 | Phase 1 | Head and Neck Cancer | Oncology | Dec 2026 |
| NCT05973487 | TSC-204-A0201 | Phase 1 | Head and Neck Cancer | Oncology | Dec 2026 |
| NCT05973487 | TSC-204-C0702 | Phase 1 | Head and Neck Cancer | Oncology | Dec 2026 |
| NCT05973487 | TSC-200-A0201 | Phase 1 | Head and Neck Cancer | Oncology | Dec 2026 |
| NCT05473910 | TSC-101 | Phase 1 | AML | Oncology | Jun 2028 |
| NCT05473910 | TSC-100 | Phase 1 | AML | Oncology | Jun 2028 |
| NCT07702578 | TSC-101 | Phase 3 | AML | Oncology | Jun 2029 |
Cash of $100m on 2026-06-30; operating cash outflow about $105m a year; runway about 11 months at that burn, to Jun 2027; 0 of 1 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Held by 2 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
–
MacroGenics Tyra Biosciences Binhui Biopharmaceutical UroGen Pharma Radiopharm Theranostics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.